

National Mobile Phlebotomy Program

Supporting Patient Care Through In-Home Blood Draws

The combined rate of diagnosis of several cancers, such as breast, colorectal and lung, has decreased by nearly 50% since the pandemic began, resulting in concerning delays in patient care and treatment! We understand that many cancer patients are anxious about visiting their physician's office or laboratory. This can make it difficult to obtain the blood draws for cancer testing that you need to provide optimal care.

At NeoGenomics, patients come first. And we're here to help.

We are excited to offer your patients access to in-home blood draws through our National Mobile Phlebotomy Program to provide the critical oncology testing they need. This will help ensure that care is delivered in a timely manner and treatment is not postponed due to testing barriers.

All mobile phlebotomy costs are covered by NeoGenomics and free to all of your cancer patients.

We provide a simple, safe, convenient process:



To request an in-home blood draw, fax the test requisition, patient demographics and insurance information to NeoGenomics

On the fax cover sheet, note whether you have given the patient a NeoGenomics Specimen Collection Kit or if we should ship one to the patient

FAX: 239-690-4237



Our mobile phlebotomy partner will contact your patient to schedule a specimen collection appointment



Employing COVID-19 precautions, a licensed phlebotomist will visit your patient and safely perform the blood draw



The specimen will be sent to NeoGenomics for analysis, and test results will be delivered to you to inform your patient's medical care

For more information contact

NeoGenomics Client Services
at 1-866-776-5907.

This program is for NeoGenomics blood-based tests, including InVisionFirst®-Lung, its advanced non-small cell lung cancer liquid biopsy test, and the NeoLAB® liquid biopsy suite of tests encompassing solid tumor and hematologic cancers.

Consider liquid biopsy testing through our National Mobile Phlebotomy Program to ensure no delays in care for your patients. Reference: 1. Kaufman HW, Chen Z, Niles J, et al. Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) pandemic. JAMA Netw Open. 2020;3(8):e2017267.

12701 Commonwealth Dr., Suite 9

Fort Myers, FL 33913

Phone: 866.776.5907 / **Fax:** 239.690.4237

neogenomics.com

© 2020 NeoGenomics Laboratories, Inc. All Rights Reserved.
All other trademarks are the property of their respective owners.
InVisionFirst is a UK, EU and US registered trade mark of Inivata Limited
CORP-MRKT-0032 Rev. 111820